title: Selective use of leuprolide acetate in women undergoing superovulation with intrauterine insemination results in significant improvement in pregnancy outcome.
abstract: OBJECTIVE
  To examine the incidence of premature luteinization in individuals undergoing hMG with IUI therapy, the association between premature luteinization, cycle fecundity, and pregnancy outcome, and to determine if the selective use of leuprolide acetate (LA) in women demonstrating premature luteinization improves pregnancy outcome in subsequent hMG with IUI cycles.
  
  
  METHODS
  Retrospective analysis of superovulation cycles from January 1990 until December 1991 at the University of Connecticut Health Center.
  
  
  METHODS
  All women with ovulatory function undergoing hMG superovulation with IUI.
  
  
  METHODS
  All patients were tested for evidence of premature luteinization. Those demonstrating premature luteinization were started on LA in the luteal phase in their subsequent hMG with IUI cycle.
  
  
  METHODS
  Peak serum E2, the number of mature preovulatory follicles, the number of ampules of hMG, days of hMG therapy, cycle fecundity, and spontaneous abortion rate.
  
  
  RESULTS
  Thirty-three percent of all hMG with IUI patients showed evidence of premature luteinization, with premature luteinization occurring in 22.2% of conception cycles and 37.4% of nonconception cycles. For those women who demonstrated premature luteinization in their conception cycle, 90.0% of the pregnancies ended with either spontaneous abortion or were biochemical in nature compared with 44.3% in the cycles without evidence of premature luteinization. Cycle fecundity was 11.1% in patients demonstrating premature luteinization compared with 26.3% for patients without premature luteinization. All women demonstrating premature luteinization and not conceiving were placed on LA in the luteal phase and had a subsequent cycle fecundity of 18.9% with the percent pregnancy wastage being significantly less (33.3% versus 90.0%) when LA was used.
  
  
  CONCLUSIONS
  Premature luteinization is a common occurrence during hMG therapy and is associated with decreased cycle fecundity and an increased incidence of spontaneous abortion and biochemical pregnancies. The selective use of LA in those individuals demonstrating premature luteinization results in a significant increase in the percent of women conceiving a viable pregnancy.
authors.affiliation: Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington.
authors.forename: D L
authors.initials: DL
authors.lastname: Manzi
authors.forename: S
authors.initials: S
authors.lastname: Dumez
authors.forename: L B
authors.initials: LB
authors.lastname: Scott
authors.forename: J C
authors.initials: JC
authors.lastname: Nulsen
mesh_terms: D000022:Abortion, Spontaneous / Q000453:epidemiology; D000328:Adult; D003338:Corpus Luteum / Q000254:growth & development; D005260:Female; D005306:Fertilization; D006801:Humans; D015994:Incidence; D007317:Insemination, Artificial, Homologous; D016729:Leuprolide / Q000627:therapeutic use*; D008183:Luteal Phase; D008297:Male; D008596:Menotropins / Q000627:therapeutic use; D011247:Pregnancy; D012189:Retrospective Studies; D013480:Superovulation; D013997:Time Factors
chemical_list: D008596:Menotropins; D016729:Leuprolide